Maarten R. Seefat

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma.

Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma.

Journal: British journal of haematology
Published: August 06, 2025

Uncovering the ultra-frail: A distinct subgroup in non-transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome.

Uncovering the ultra-frail: A distinct subgroup in non-transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome.

Journal: HemaSphere
Published: July 31, 2025

Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial.

Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial.

Journal: Blood advances
Published: June 09, 2025

Adaptive designs in randomized clinical trials: reanalysis of the HOVON87/NMSG18 multiple myeloma trial.

Adaptive designs in randomized clinical trials: reanalysis of the HOVON87/NMSG18 multiple myeloma trial.

Journal: EClinicalMedicine
Published: April 20, 2025

Whole Body Physiologically Based Pharmacokinetic Model to Explain A Patient With Drug-Drug Interaction Between Voriconazole and Flucloxacillin.

Whole Body Physiologically Based Pharmacokinetic Model to Explain A Patient With Drug-Drug Interaction Between Voriconazole and Flucloxacillin.

Journal: European journal of drug metabolism and pharmacokinetics
Published: August 18, 2024

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma.

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma.

Journal: Blood
Published: June 25, 2024

Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes.

Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes.

Journal: HemaSphere
Published: February 16, 2024

Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trial.

Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trial.

Journal: European journal of cancer (Oxford, England : 1990)
Published: February 02, 2024

Treatment sequences and drug costs from diagnosis to death in multiple myeloma.

Treatment sequences and drug costs from diagnosis to death in multiple myeloma.

Journal: European journal of haematology
Published: June 29, 2023

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13.

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13.

Journal: HemaSphere
Published: May 11, 2023

Impact of Comorbidities on Health-related Quality of Life in Nontransplant Eligible Patients With Newly Diagnosed Multiple Myeloma.

Impact of Comorbidities on Health-related Quality of Life in Nontransplant Eligible Patients With Newly Diagnosed Multiple Myeloma.

Journal: HemaSphere
Published: February 16, 2022

A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma.

A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma.

Journal: Cancers
Published: August 30, 2021
Showing 1-12 of 12

Last Updated: 09/26/2026